Prostate cancer is one of the most commonly diagnosed cancers worldwide, and the number of newly diagnosed patients is increasing commensurate with an aging population (1) Prostate-specific membrane antigen (PSMA)–ligand PET/CT is increasingly used in the initial staging of high-risk tumors and in identifying sites of recurrence. The gene discussed is FOLH1; the disease is prostate carcinoma.